Literature DB >> 16512786

Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

Anna L Remoli1, Giulia Marsili, Edvige Perrotti, Eleonora Gallerani, Ramona Ilari, Filomena Nappi, Aurelio Cafaro, Barbara Ensoli, Riccardo Gavioli, Angela Battistini.   

Abstract

The Tat protein is the transcriptional activator of HIV-1 gene expression, which is not only essential for viral replication, but also important in the complex HIV-induced pathogenesis of AIDS, as both an intracellular and an extracellular released protein. Accordingly, Tat is able to profoundly affect cellular gene expression, regulating several cellular functions, also in non-infected cells. We showed recently that Tat induces modification of immunoproteasomes in that it up-regulates LMP7 (low-molecular-mass polypeptide 7) and MECL1 (multicatalytic endopeptidase complex-like 1) subunits and down-modulates the LMP2 subunit, resulting in a change in the generation and presentation of epitopes in the context of MHC class I. In particular, Tat increases presentation of subdominant and cryptic epitopes. In the present study, we investigated the molecular mechanism responsible for the Tat-induced LMP2 down-regulation and show that intracellular Tat represses transcription of the LMP2 gene by competing with STAT1 (signal transducer and activator of transcription 1) for binding to IRF-1 (interferon-regulatory factor-1) on the overlapping ICS-2 (interferon consensus sequence-2)-GAS (gamma-interferon-activated sequence) present in the LMP2 promoter. This element is constitutively occupied in vivo by the unphosphorylated STAT1-IRF-1 complex, which is responsible for the basal transcription of the gene. Sequestration of IRF-1 by intracellular Tat impairs the formation of the complex resulting in lower LMP2 gene transcription and LMP2 protein expression, which is associated with increased proteolytic activity. On the other hand, extracellular Tat induces the expression of LMP2. These effects of Tat provide another effective mechanism by which HIV-1 affects antigen presentation in the context of the MHC class I complex and may have important implications in the use of Tat for vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16512786      PMCID: PMC1462712          DOI: 10.1042/BJ20051570

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

1.  c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.

Authors:  R Gavioli; T Frisan; S Vertuani; G W Bornkamm; M G Masucci
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

2.  Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors.

Authors:  Shin Sasaki; Rama Rao Amara; Wen-Shuz Yeow; Paula M Pitha; Harriet L Robinson
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

3.  Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector.

Authors:  A Caputo; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 4.  Viral strategies of immune evasion.

Authors:  H L Ploegh
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

5.  Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription.

Authors:  Giulia Marsili; Anna Lisa Remoli; Marco Sgarbanti; Angela Battistini
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

6.  Requirement for IRF-1 in the microenvironment supporting development of natural killer cells.

Authors:  K Ogasawara; S Hida; N Azimi; Y Tagaya; T Sato; T Yokochi-Fukuda; T A Waldmann; T Taniguchi; S Taki
Journal:  Nature       Date:  1998-02-12       Impact factor: 49.962

7.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

8.  Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins.

Authors:  Antonio Fittipaldi; Aldo Ferrari; Monica Zoppé; Caterina Arcangeli; Vittorio Pellegrini; Fabio Beltram; Mauro Giacca
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

9.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

Authors:  P André; M Groettrup; P Klenerman; R de Giuli; B L Booth; V Cerundolo; M Bonneville; F Jotereau; R M Zinkernagel; V Lotteau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more
  20 in total

1.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Sunita Gupta; Jeffrey N Keller; Pamela E Knapp; Kurt F Hauser; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2008-11-19       Impact factor: 5.372

3.  HIV Tat-mediated transcriptional regulation of proteasome protein cleavage specificity.

Authors:  Cristina Aresté; David J Blackbourn
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

4.  Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes.

Authors:  Valentina Muto; Emilia Stellacci; Angelo Giuseppe Lamberti; Edvige Perrotti; Aurora Carrabba; Giovanni Matera; Marco Sgarbanti; Angela Battistini; Maria Carla Liberto; Alfredo Focà
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

5.  Patterns of HIV-1 protein interaction identify perturbed host-cellular subsystems.

Authors:  Jamie I MacPherson; Jonathan E Dickerson; John W Pinney; David L Robertson
Journal:  PLoS Comput Biol       Date:  2010-07-29       Impact factor: 4.475

6.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

7.  IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer.

Authors:  Marco Sgarbanti; Anna L Remoli; Giulia Marsili; Barbara Ridolfi; Alessandra Borsetti; Edvige Perrotti; Roberto Orsatti; Ramona Ilari; Leonardo Sernicola; Emilia Stellacci; Barbara Ensoli; Angela Battistini
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

8.  Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins.

Authors:  Magnus Sundstrom; Udayan Chatterji; Lana Schaffer; Sohela de Rozières; John H Elder
Journal:  Virology       Date:  2007-10-25       Impact factor: 3.616

9.  Renal HIV expression is unaffected by serum LPS levels in an HIV transgenic mouse model of LPS induced kidney injury.

Authors:  Jeremy S Leventhal; Zygimantas Alsauskas; Alexandra Snyder; Pengfei Gong; Bin Wang; Vivette D'Agati; Michael J Ross
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

Review 10.  Role of proteasomes in disease.

Authors:  Burkhardt Dahlmann
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.